What trends are shaping pharmaceutical M&A in China?

In this exclusive report you’ll get an in-depth analysis of cross-border transactions in Chinese pharma, revealing how the industry evolved in 2025 and what it means for M&A in 2026.

Created in partnership with Haoyue Capital, the report examines four key trends:

  1. Why licence-out continues to dominate.
  2. The increasing complexity of deal structures
  3. How digital due diligence is accelerating deal timelines
  4. The continued shift towards earlier development stages

It also includes detailed analysis of deal data from 2023-2025 and reveals the top 10 pharma transactions led by Chinese companies in 2025.

Download the report today.

Get the white paper and make your next transaction more effective

Download started

If your download hasn’t started, please, click here